Manish Patel, DO, discussed the unmet needs that led to the investigation of ADT plus pembrolizumab in patients with advanced salivary gland carcinoma.
Back
Dr Patel on the BTCRC HN17-111 Trial of ADT Plus Pembrolizumab in Salivary Gland Cancer
Dr Patel on the BTCRC HN17-111 Trial of ADT Plus Pembrolizumab in Salivary Gland Cancer
Episodes
All
All
Manish Patel, DO, discussed the single-arm BTCRC HN17-111 study investigating ADT plus pembrolizumab in advanced, AR-positive salivary gland cancer.
Manish Patel, DO, discusses response rates seen with ADT in combination with pembrolizumab in advanced, androgen receptor–positive salivary gland cancer.
Manish Patel, DO, discusses AEs seen with ADT plus pembrolizumab in patients with advanced-stage, androgen receptor–positive salivary gland cancer.
Manish Patel, DO, discusses future directions for investigating hormonal plus immune therapies for the treatment of patients with salivary gland cancer.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer
2
Daraxonrasib Yields Durable Responses in Previously Treated RAS-Mutant NSCLC
3
Novel Analysis Reveals Millions of Life-Years Saved by Blood Cancer Treatments
4
Ivonescimab Meets OS End Point vs Pembrolizumab in First-Line PD-L1+ NSCLC
5